Gilead Sciences Update On The Company’s Ongoing Response To COVID-19
Gilead is working closely with global health authorities to respond to the novel coronavirus (COVID-19) outbreak through the appropriate experimental use of the investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS), National Institute of Allergies and Infectious Diseases (NIAID) and Department of Defense (DoD) - CBRN Medical; the China CDC and National Medical Product Administration (NMPA); the World Health Organization (WHO); and researchers and clinicians across Europe and Asia; Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting COVID-19.
Learn more about our efforts:
- About Remdesivir
- An Open Letter from our Chairman & CEO – March 28, 2020
- An Update from our Chairman & CEO – April 4, 2020
- An Open Letter from our Chairman & CEO – April 10, 2020
- An Open Letter from our Chairman & CEO – April 29, 2020
- Supply of Approved Products
- Ongoing Support for Community Organizations
Access to Remdesivir and Future Study
Gilead is mapping out options to make access to investigational remdesivir more widely available through expedited regulatory processes should it demonstrate the potential to be a safe and effective treatment option based on the results of preliminary clinical trials.
Gilead is also in discussion with multiple organizations regarding the potential for future trials.
For More Information:
Please contact Gilead via email with any questions by clicking here.
Last Updated: April 29, 2020